| Full text | |
| Author(s): |
Izar, Maria C.
[1, 2]
;
Fonseca, Henrique A.
[1]
;
Pinheiro, Luiz F.
[1]
;
Monteiro, Carlos M.
[1]
;
Povoa, Rui M.
[1]
;
Monteiro, Andrea M.
[3, 2]
;
Figueiredo-Neto, Antonio M.
[2]
;
Gidlund, Magnus A.
[3]
;
Fonseca, Francisco A.
[1, 2]
Total Authors: 9
|
| Affiliation: | [1] Univ Fed Sao Paulo, Dept Med, Div Cardiol, BR-04039030 Sao Paulo - Brazil
[2] Univ Sao Paulo, Natl Inst Complex Fluids, Inst Phys, BR-05508 Sao Paulo - Brazil
[3] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | Diabetes & Vascular Disease Research; v. 10, n. 1, p. 32-39, JAN 2013. |
| Web of Science Citations: | 9 |
| Abstract | |
Metabolic syndrome (MetS) is an inflammatory state associated with high coronary disease risk. Inflammation and adaptive immunity modulate atherosclerosis and plaque instability. We examined early changes in anti-oxidized low-density lipoprotein (LDL) (anti-oxLDL) autoantibodies (Abs) in patients with MetS after an acute coronary syndrome (ACS). Patients of both genders (n=116) with MetS were prospectively included after an acute myocardial infarction (MI) or hospitalization due to unstable angina. Anti-oxLDL Abs (IgG class) were assayed at baseline, three and six weeks after ACS. The severity of coronary disease was evaluated by the Gensini score. We observed a decrease in anti-oxLDL Abs titers (p<0.002 vs. baseline), mainly in males (p=0.01), in those under 65 y (p=0.03), and in subjects with Gensini score above median (p=0.04). In conclusion, early decrease in circulating anti-oxLDL Abs is associated with coronary disease severity among subjects with MetS. (AU) | |
| FAPESP's process: | 04/00325-8 - Efeitos pleitropicos precoces do fenofibrato e atorvastatina, isolados ou combinados, apos sindrome coronariana aguda em pacientes com sindrome metabolica. |
| Grantee: | Francisco Antonio Helfenstein Fonseca |
| Support Opportunities: | Regular Research Grants |